All Stories

  1. Prevention in Hepatology
  2. Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC
  3. Choosing wisely recommendations regarding the top five list of procedures to avoid in the treatment of viral hepatitis: A position statement from the Brazilian Society of Hepatology endorsed by the Latin American Association for the Study of the liver
  4. Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF‐β1/pERK signaling pathway
  5. Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries
  6. Implementation of a re‐linkage to care strategy in patients with chronic hepatitis C who were lost to follow‐up in Latin America
  7. Serious liver injury induced by Nimesulide: an international collaborative study
  8. Editorial: biomarkers in HBV and prediction of treatment response
  9. Direct‐acting antiviral treatment failure in genotype 2 hepatitis C chronic infection
  10. Seroprevalence of hepatitis B, hepatitis C and HIV infection among patients undergoing haemodialysis in Buenos Aires, Argentina
  11. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents
  12. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma
  13. Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real‐world experience from HCV‐LALREAN cohort
  14. The liver in times of COVID-19: What hepatologists should know
  15. Hepatitis E infection is an infrequent cause of acute hepatitis in the metropolitan area of Buenos Aires
  16. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
  17. Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
  18. Hepatitis B virus infection as a risk factor for chronic kidney disease
  19. The ECHO model proved to be a useful tool to increase clinicians' self‐effectiveness for care of patients with Hepatitis C in Argentina
  20. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance‐associated substitutions in naïve patients from Argentina
  21. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis
  22. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin
  23. ¿Qué estrategias deben implementarse en Latinoamérica para erradicar el virus de la hepatitis C antes de 2030?
  24. FRI-078-Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases
  25. Treatment with direct‐acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma
  26. Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
  27. Molecular epidemiology of hepatitis B virus mutants associated with vaccine escape, drug resistance and diagnosis failure
  28. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?
  29. Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges
  30. Editorial: grey zone, a new area of interest in chronic hepatitis B
  31. Potential molecular targets of statins in the prevention of hepatocarcinogenesis
  32. Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice
  33. Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
  34. Incidence of de-novo hepatocellular carcinoma after treatment with direct antiviral agents for hepatitis C: A multicenter prospective cohort study from Latin America
  35. Safety and effectiveness comparing generic and original sofosbuvir-based treatment regimens in patients with hepatitis C: A prospective multicenter study from Argentina
  36. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina
  37. Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups
  38. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K
  39. NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b
  40. Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America
  41. Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population
  42. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
  43. Clinical epidemiology of acute hepatitis C in South America
  44. Hepatotoxicity induced by coxibs: how concerned should we be?
  45. Hepatitis C virus infection in Argentina: Burden of chronic disease
  46. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2
  47. Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3
  48. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2
  49. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2
  50. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?
  51. Ultra-sensitive procalcitonin may help rule out bacterial infections in patients with cirrhosis
  52. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice
  53. Safety of direct-acting antivirals in the treatment of chronic hepatitis C
  54. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir
  55. Antiviral treatment for chronic hepatitis B in renal transplant patients
  56. Hepatitis C Virus Diversification in Argentina: Comparative Analysis between the Large City of Buenos Aires and the Small Rural Town of O'Brien
  57. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir
  58. Syncope during boceprevir treatment in hepatitis C
  59. Predictors of response to chronic hepatitis C treatment
  60. Increased mortality in chronic HCV infection
  61. Entecavir in the treatment of chronic hepatitis B in kidney transplantation
  62. Safety of long-term nucleos(t)ide treatment in chronic hepatitis B
  63. Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin
  64. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
  65. Breath-Ammonia Testing of Healthy Subjects and Patients with Cirrhosis
  66. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice
  67. Thioctic Acid–Induced Acute Cholestatic Hepatitis
  68. 141 BREATH AMMONIA TESTING OF HEALTHY SUBJECTS AND PATIENTS WITH CIRRHOSIS
  69. 1177 INTERLEUKIN-28B PREDICTS SVR IN LATIN AMERICAN HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH PEG IFN AND RIBAVIRIN
  70. Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ‘true life’
  71. Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation
  72. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients
  73. 1071 SHORT AND LONG TERM OUTCOME OF KIDNEY TRANSPLANTED PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C
  74. Hepatitis C treatment completion rates in routine clinical care
  75. Predictors of response to chronic hepatitis C treatment
  76. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon – Ribavirin in daily practice
  77. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study
  78. Hepatitis C Virus Infection and Outcome of Renal Transplantation
  79. Imatinib-induced fatal acute liver failure
  80. Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin
  81. Chylous ascites as the main manifestation of left ventricular dysfunction: a case report
  82. Hepatocellular Carcinoma in Renal Transplant Patients
  83. POLYMYALGIA RHEUMATICA PRESENTING AS ACUTE CHOLESTATIC HEPATITIS
  84. CASE REPORT: Severe Cholestatic Hepatitis as the First Symptom of Secondary Syphilis
  85. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin